The United States Food and Drug Administration granted accelerated regulatory approval for a breakthrough genetic therapy proven to halt cognitive decline in early-stage Alzheimer disease patients, offering unprecedented medical hope while raising immediate national concerns over the projected forty thousand United States dollar annual treatment cost.